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PREVIOUSLY,  we  found  that  inflammatory  mediators
modulated the number and binding affinity of gluco-
corticoid receptors (GR) in human bronchial epithe-
lial cell lines. In this study we investigated whether
smoking and chronic obstructive pulmonary disease
(COPD), both characterized by airway inflammation
with  increased  levels  of  inflammatory  mediators,
affect GR characteristics in cultured human bronchial
epithelial cells (HBEC). A statistically significant dif-
ference was found between the dissociation constant
(Kd)  values  in  HBEC  from  smoking  (Kd =  0.98  ±
0.08 nM; n = 6) and nonsmoking controls (Kd = 0.76 ±
0.10 nM, P = 0.03; n = 5), but no significant difference
was  found  between  the  mean  number  of  binding
sites. Our results are the first indication that cultured
HBEC from smokers possess GR with a lower binding
affinity. This may result from the inflammation found
in  the  airways  from  smokers.  Furthermore,  these
results  provide  further  evidence  that  the  bronchial
epithelium  may  be  an  actual  target  for  inhaled
glucocorticoid therapy.
Key  words:  Glucocorticoid  receptors,  Human  bronchial
epithelial  cells,  Chronic  obstructive  pulmonary  disease,
Smoking
Introduction
The bronchial epithelium has long been regarded as
a  passive  barrier  to  protect  the  underlying  tissue.
1
Now,  bronchial  epithelial  cells  are  also  known  to
play an active role in airway inflammation. They are
able  to  produce  various  inflammatory  mediators
including  cytokines  and  eicosanoids.
2,3 Bronchial
epithelial  cells  recovered  from  asthmatic  patients
show  increased  gene  expression  for  GM-CSF ,  IL-6
and  IL-8.
3 Furthermore,  increased  expression  of
endothelin-1,  TNF-a ,  IL-1ß  and  MCP-1  has  been
demonstrated.
4,5
Glucocorticoids are widely used in the treatment of
inflammatory  pulmonary  diseases,  e.g.  bronchial
asthma  and  chronic  obstructive  pulmonary  disease
(COPD)
6 Recent studies showed that glucocorticoids
are  able  to  inhibit  the  release  of  some  bronchial
epithelial  cell-derived  cytokines.
3,7 These  effects  of
glucocorticoids combined with the above-mentioned
role of bronchial epithelial cells in airway inflamma-
tion,  suggest  that  glucocorticoid  therapy  may  sup-
press  airway  inflammation,  at  least  partially,  by
modulating the function of bronchial epithelial cells.
This hypothesis is supported by the observation that
the greater part of inhaled glucocorticoids precipitate
on  the  epithelium  of  the  larger  airways.
8 A  pre-
requisite for steroid responsiveness is the presence of
specific glucocorticoid receptors (GR).
In a recent study we identified and characterized
specific  GR  in  two  SV-40/adenovirus-transformed
human  bronchial  epithelial  cell  lines,  BEAS  2B  and
BEAS  S6.
9 We  also  demonstrated  that  inflammatory
mediators such as IL-1ß and  LPS may modulate the
number and  the  binding affinity  of  GR in  BEAS  2B
cells. Similar results were found by other investigators
in  human  T  cells,  other  cell  lines  and  murine
macrophages.
10 –12 These results indicate that inflam-
matory processes may influence the response of the
bronchial  epithelium  to  glucocorticoid  therapy  via
locally produced cytokines.
Here, as an extension of our findings in cell lines,
we report on the identification  and characterization
of specific GR in cultured human bronchial epithelial
cells  (HBEC).  From  the  above-mentioned  in  vitro
findings  concerning  the  effects  of  inflammatory
mediators on GR, it may be expected that inflamma-
tion  in  vivo may  also  affect  GR  characteristics.
Therefore, we also studied whether in cultured HBEC
from smokers and COPD patients, in whom general
inflammation  has  been  described,
13 the  number  or
binding affinity of GR is altered.
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Subjects
A  total  of  19  subjects  were  entered  into  the  study
(Table 1). Of the subjects eight fulfilled ATS criteria for
COPD.
14 COPD patients were nonallergic with com-
plaints  of  chronic  cough  and  sputum  production.
Chronic cough means that coughing occurs on most
days during at least three consecutive months in two
consecutive  years.  One-second  forced  expiratory
volume  (FEV1)  was measured  in  all  subjects before
entry  into  the  study.  COPD  patients  suffered  from
major airway obstruction, that is, the FEV1 was <75%
of predicted. No reversibility of airway obstruction in
these eight patients was obtained after inhalation of
0.5 mg terbutaline. Controls (n = 11) were subjects
who denied any symptoms of asthma or COPD, and
had normal lung function parameters. The COPD and
control group contained five and six smoking individ-
uals, respectively. From the nonsmoking controls one
individual  stopped  smoking  12  years  ago.  Smoking
individuals  were  current  smokers  with  a  smoking
history of at least 35 pack-years.
Isolation and culture conditions of HBEC
Bronchial  tissue  was  obtained  from  patients  under-
going surgery for lung cancer and used immediately
for  culture  of  HBEC  by  a  cell  culture  method
described  previously.
15 Briefly,  bronchial  tissue  dis-
tant  from  the  tumour  was  cut  into  pieces  and
incubated either overnight at 4°C or  1 h at  37°C in
0.1%  protease  XIV  (Sigma,  St  Louis,  MO).  Subse-
quently, epithelial cells were gently scraped from the
tissue samples, washed twice in culture medium and
plated onto 35-mm dishes at a density of 2.5 3 10
5
cells/dish.  HBEC  were cultured  in  a  1:1  mixture  of
Dulbecco’s modified Eagle’s medium and Ham’s F12
(DMEM/F12)(GIBCO, Paisley, UK), with supplements
as described previously.
15 Cells were characterized as
epithelial cells by immunofluorescence staining using
a  mouse  monoclonal  antibody  directed  against  a
number  of  human  cytokeratins  (CK-1;  DAKOpatts,
Glostrup, Denmark). At least 99% of the isolated cells
stained positive for cytokeratin.
When dishes were confluent, HBEC were passaged
to  75 cm
2 flasks  and  used  for  experiments  after
confluence. Twenty-four hours before performing GR
binding experiments the medium was replaced by a
basal medium of DMEM/F12 (1:1) with penicillin G
sodium  and  streptomycin  sulphate,  but  without
hydrocortisone  or  other  supplements  to  prevent
influence of endogenous steroids on the number and
affinity of GR.
Cell lines
BEAS  2B  is  a  SV-40/adenovirus  transformed  human
bronchial  epithelial  cell  line,  which  was  kindly
provided  by  Dr  J.  Lechner  (Inhalation  Toxicology
Research  Institute, Albuquerque,  NM).
16 Cells  were
maintained  in  a  complete  keratinocyte  growth
medium (KGM) containing bovine pituitary extract,
EGF, penicillin G sodium and streptomycin sulphate
(GIBCO).
The COS-1 cell line was used as a negative control
for GR Western blot experiments. The COS-1 cell line,
derived from the kidney of a male adult African green
monkey  (American  Type  Culture  Collection,  Rock-
ville, MD) was cultured in DMEM with 5% FCS.
Preparation of cytosol
Flasks containing approximately 10 3 10
6 cells were
washed  twice  with  cold  phosphate  buffered  saline
(PBS) and HBEC were scraped in 0.5 ml of buffer A
(40 mM  Tris-HCI  pH  7.4,  1mM  EDTA,  10%  (v/v)
glycerol,  10 mM  dithiothreitol,  10 mM  Na2MoO4)
supplemented  with  0.6 mM  phenylmethylsulphonyl
fluoride  (PMSF),  0.5mM  bacitracine  and  0.5 mM
leupeptin. The cells were lysed by freezing/thawing
three times and the homogenate was centrifuged for
10 min  at  400 000  3 g.
17 The  supernatant  was
collected and stored at –80°C. Protein concentrations
were determined according to the method of Brad-
ford
18 and ranged from 1 to 2 m g/m l. Cytosol prepara-
tions were used for both Western blotting and binding
assays.
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Nonsmoking controls 5 71 ± 2 0 87 ± 6
Smoking controls 6 59 ± 3 ‡  35 90 ± 4
Nonsmoking COPD patients 3 67 ± 1 0 68 ± 6
Smoking COPD patients 5 60 ± 3 ‡  35 52 ± 3
Data are shown as mean ± SEM.Western blotting
Samples  (20 m l  cytosol  containing  1 m g/m l  protein)
were  mixed  with  5m l  of  5  3 sample  buffer  (1  3
sample  buffer  =  50 mM Tris-HCI  pH  6.8,  10%  (v/v)
glycerol, 2% (w/v) SDS, 10mM dithiothreitol, 0.001%
(w/v)  bromophenol  blue),  boiled  for  2.5 min  and
separated on a 7% SDS-PAGE gel. After electrophoresis
the gels were blotted to nitrocellulose membrane in
blotting  buffer  (16.5 mM Tris-HCl,  pH  8.3,  150 mM
glycine and 20% v/v methanol). The membranes were
blocked  for  1 h  at  RT  with  1%  block  solution
(Boehringer, Mannheim, Germany) and incubated for
1 h at  room temperature with  a  commercially  avail-
able GR polyclonal rabbit antibody, no. 57 (PA1–511;
Affinity  Bioreagents,  Neshanic  Station,  NJ),  diluted
1:250  in  0.5%  block  solution.  Membranes  were
washed twice with PBS/T ween 0.1% and twice with
0.5% block solution, then incubated with horseradish
peroxidase-conjugated goat anti-rabbit-IgG (Sigma) for
1 h at RT . After 4 3 15 min washes (PBS/T ween 0.1%)
proteins were detected with Boehringer-Mannheim’s
Chemiluminescence Western  Blotting  kit  and  mem-
branes were exposed to X-ray film.
Steroids
3H-labelled  dexamethasone  (1,2,4,6,7  [
3H]  dexame-
thasone; specific activity 81 Ci/mmol) was obtained
from Amersham (Buckinghamshire, UK). Nonradioac-
tive dexamethasone was kept in a stock solution of 2
3 10
–3 M  in  ethanol  (Duchefa  bv.  Haarlem,  the
Netherlands).
Binding assays
GR numbers and Kd values were determined accord-
ing  to  established  methods.
19 Six  serial  doubling
dilutions (50m l) were prepared in duplicate in PBS to
final 
3H-labelled dexamethasone concentrations of 32,
16, 8, 4, 2, and  1nmol/l, respectively. For measure-
ments  of  nonspecific  binding,  parallel  dilutions  of
3H-labelled  dexamethasone  plus  a  100-fold  molar
excess  of  nonradioactive  dexamethasone  were  pre-
pared. To each of the 24 tubes 150 m l of the cytosol
preparation  was  added  and  the  mixture  was  incu-
bated  overnight  at  4°C.  Binding  equilibrium  was
reached  at  all  concentrations  after  incubation  over-
night  at  4°C.  Subsequently,  160 m l  aliquots  of  each
incubation  mixture  were  transferred  to  albumin
(0.1%)  coated  tubes,  750 m l  of  protamine  dihy-
drochloride  solution  (0.5 mg/ml)  was  added  and
tubes were centrifuged for 15 min at 4000rpm. From
the remaining incubation mixture 20 m l was used to
establish the exact concentration of 
3H-labelled dex-
amethasone. Tubes  containing  protein  pellets  were
washed  three  times  with  1ml  of  incubation  buffer
(50 mM Tris-HCI pH 7.4, 1.5 mM EDTA, 1.5 mM DTT,
10% glycerol) and pellets were solubilized in Soluene-
350 (Packard, Meriden, CT). Thereafter, samples were
transferred to scintillation vials and radioactivity was
determined by liquid scintillation counting. Specific
binding was calculated as the difference between the
totally  bound  radioactivity  and  the  nonspecifically
bound radioactivity at each glucocorticoid concentra-
tion.  Nonspecific  binding  was  calculated  from  the
aliquots  containing  the  100-fold  molar  excess  non-
radioactive  dexamethasone,  assuming  that  nonspe-
cific binding was nonsaturable and linearly related to
the concentration of free glucocorticoid.
Analysis
Binding  curves  were  constructed  from  increasing
concentrations of 
3H-dexamethasone. GR number and
Kd values were determined by Scatchard analysis of
these  data.  Data  were  expressed  as  mean  fmol/mg
protein specific binding ± the standard  error of the
mean  (SEM).  The  Wilcoxon  Matched-Pair  Signed-
Ranks  test  was  used  to  assess  the  equality  of  GR
number and Kd distributions in HBEC from patients
with COPD and controls. A P-value of less than 0.05
was considered significant.
Results
Expression of glucocorticoid receptor protein in
normal HBEC
Cytosolic fractions were isolated from HBEC, BEAS 2B
and  COS-1  cells,  and  GR  levels  were  examined  by
Western blotting. The GR polyclonal rabbit  antibody
Glucocorticoid receptors in bronchial epithelial cells
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FIG. 1. Western blot of 20m g protein illustrating immunor-
eactive GR levels in cultured human bronchial epithelial cells
(BE)  and  in  the  cell  line  BEAS  2B.  One  representative
experiment out of three is shown. The COS-1 cell line (20m g)
was used as a negative control.recognized a prominent band at ~97 kDa in the HBEC
and  BEAS  2B  preparations  (Fig.  1). This  estimated
molecular  mass  is  consistent  with  that  reported
previously for the human  GR.
20 In the GR negative
cell  line  COS-1,  no  immunoreactive  protein  was
detectable.
After  demonstrating  the  presence  of  GR  protein,
the  number  of  GR  and  Kd values  were  studied  in
cultured HBEC from controls (n = 11). Using estab-
lished methods to identify GR, we could demonstrate
specific  binding  of 
3H-labelled  dexamethasone  by
these cells. A typical binding curve for cultured HBEC
is shown  in  Fig. 2A. After Scatchard  analysis  of the
data,  the linear  regression  line obtained indicated a
single class of GR (Fig. 2B).
GR binding in HBEC COPD patients, smokers
and controls
HBEC were isolated from bronchus tissue from eight
COPD  patients  and  11  controls.  The  COPD  and
control group contained five and six smoking individ-
uals, respectively. Cells were cultured for one passage.
Thereafter, cytosols were prepared and the number of
glucocorticoid binding sites and Kd were determined.
Results  are  presented  in  Table  2  and  Fig.  3.  A
significant  difference  was  found  between  the  Kd
values in HBEC from smoking (Kd = 0.98 ± 0.08 nM)
and nonsmoking controls (Kd = 0.76 ± 0.10nM, P =
0.03),  but  no  significant  difference  was  found
between the mean number of binding  sites (70.5 ±
M. M. Verheggen et al.
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FIG. 2. (A) Binding curve of 3H-labelled dexamethasone for cultured HBEC. The specific binding is represented by the difference
between the total and nonspecific binding. The data points represent mean values of duplicate determinations. (B) Scatchard
plot of the specific binding of 
3H-labelled dexamethasone to HBEC. On the ordinate is given the ratio of the number of
specifically bound 3H-labelled dexamethasone (Bs) to the number of free 3H-labelled dexamethasone (F). One representative
experiment out of 11 is shown. The Kd and the number of glucocorticoid binding sites permg protein (R) were calculated using
the negative inverse of the slope and the 3 intercept, respectively.
Table 2. Glucocorticoid binding in HBEC from smoking and nonsmoking COPD patients and controls
Controls COPD patients
Nonsmoking (n = 5) Smoking (n = 6) Nonsmoking (n = 3) Smoking (n = 5)
R (fmol/mg protein) 87.2 ± 16.7 70.5 ± 14.0 79.7 ± 22.6 68.4 ± 12.8
Kd (nM) 0.76 ± 0.10 0.98 ± 0.08* 0.74 ± 0.19 0.71 ± 0.15
Data are shown as mean ± SEM. R: number of glucocorticoid binding sites; Kd: dissociation constant. *: significantly higher (P < 0.05) than in
nonsmoking controls.14.0 and 87.2 ± 16.7 fmol/mg protein, respectively, P
= 0.3). Furthermore, values measured in nonsmoking
and  smoking  COPD  patients (P =  0.6  and  P = 0.6,
respectively) did not differ significantly. Nor was any
significant  difference  observed  in  glucocorticoid
binding  sites  or  Kd between  nonsmoking  COPD
patients and nonsmoking controls (P = 0.6 and P =
0.6, respectively) or between smoking COPD patients
and  smoking  controls  (P =  0.9  and  P =  0.1,
respectively).
Discussion
In this study we identified and characterized specific
GR in primary cultures of HBEC from COPD patients
and  controls.  The  presence  of  GR  protein  was
demonstrated  using  Western  blot  analysis  and
3H-dexamethasone  binding  studies.  A  significant
decrease was found in the binding affinity  of GR in
HBEC  from  smoking  controls  compared  with  non-
smoking controls, but  no significant  difference was
found between the mean number of specific gluco-
corticoid binding sites. Furthermore, values measured
in nonsmoking and smoking COPD patients did not
differ significantly. Nor was any difference observed
between the mean number of binding sites and the Kd
values in HBEC from nonsmoking COPD patients and
the  values  measured  in  nonsmoking  controls  or
between  the  values  measured  in  smoking  COPD
patients and smoking controls.
HBEC are considered to play an important role in
airway  inflammation.
1–5 Inhaled glucocorticoids are
used  to  suppress  airway  inflammation  and,  con-
comitantly, to improve clinical parameters. The find-
ing  that  HBEC  possess  functional  GR  allows  us  to
hypothesize  that  the  clinical  response  to  inhaled
glucocorticoids,  which  mainly  precipitate  in  the
larger  airways,  results,  at  least  partly,  from  the
modulation of airway epithelial cell functions. From
the  Kd value  of  the  GR  in  HBEC  observed  in  our
studies,  we  expect  that  effective  in  vivo gluco-
corticoid concentrations should be around 1 nM. In a
recent study by Van den Bosch et al.
21 it was shown
that at least 90 min after inhalation of 1.6 mg budeso-
nide, lung tissue concentrations ranged from 2.1 to
8.9 nM. Therefore, we can assume that therapeutical
inhalation of glucocorticoids results in such concen-
trations  of  glucocorticoids  in  lung tissue  that  inter-
action with GR in HBEC will occur.
In a previous study we found that the SV-40/adeno-
virus transformed human bronchial epithelial cell line
BEAS 2B contained a higher number of glucocorticoid
binding sites compared with peripheral blood mono-
nuclear cells (PBMC).
8 The number and quality of GR
in  target  cells  may  determine  the  extent  of  gluco-
corticoid  responsiveness.
22 HBEC were observed to
contain less GR than the BEAS 2B cell line (87.4 ± 16.5
and  370  ±  14 fmol/mg  protein,  respectively).  This
difference  may  be  caused  by  the  SV-40/adenovirus
transformation. HBEC contain a relatively high num-
Glucocorticoid receptors in bronchial epithelial cells
Mediators of Inflammation · Vol 7 · 1998 279
FIG. 3. Total number of GR (A) and Kd values (B) in cultures of HBEC from nonsmoking controls (n = 5), smoking controls (n
= 6), nonsmoking COPD patients (n = 3) and smoking COPD patients (n = 5). Data are shown as mean ± SEM. * P < 0.05 for
smoking controls versus nonsmoking controls. sm: smoking.ber  of  GR  compared  with  PBMC,  which  contain
approximately  30fmol/mg  protein  (unpublished
results).  It  would  be  interesting  to  investigate
whether  these  differences  in  GR  number  result  in
differences  in  the  functional  response  to  gluco-
corticoids. As both epithelial cells and PBMC are able
to produce IL-1ß, the inhibition of IL-1ß production
by glucocorticoids may be a useful parameter to study
this issue. Few data are available on the number of GR
in other epithelial cells. A human epithelial duct cell
line  was  found  to  contain  83–92 fmol  GR/mg
protein.
23
Previously, we demonstrated that the inflammatory
mediators  IL-1ß  and  LPS  increased  the  GR  number
and Kd in BEAS 2B cells.
8 Similar results were found in
other cell types.
9–11 These results suggest that inflam-
matory  processes  may  indirectly  influence  the
response  of  bronchial  epithelium  to  glucocorticoid
therapy  via  production  of  cytokines  by  infiltrating
cells. It has been suggested that in COPD, bronchial
inflammation  is responsible for the development  of
airway  hyperreactivity,  and  chronic  airflow  limita-
tion.
12 Cigarette  smoking  causes  an  inflammatory
reaction in the airways and can lead to the develop-
ment of COPD.
13 We found a significantly decreased
binding affinity of the GR in smoking controls when
compared with values found in nonsmoking controls.
These results indicate that the inflammation present
in the airways of smokers may influence the binding
affinity  of  GR  receptors. The  finding  that  in  vivo
inflammation found in smokers affects GR character-
istics  in  HBEC  is  in  accordance  with  our  above
mentioned  findings  in  vitro.  However,  we  did  not
find any difference in the binding affinity of the GR in
smoking COPD patients when compared with values
in nonsmoking COPD patients. A study by Linden et
al.
13 showed that obstructed smoking COPD patients
had  significantly  lower  concentrations  of  inflamma-
tory cells in the bronchial lavage fluid compared with
nonobstructed smoking individuals. Therefore, it was
suggested that obstructed and nonobstructed smok-
ers  may  differ  in  the  type  of  airway  inflammation
present.  The  presence  of  lower  concentrations  of
inflammatory  cells  in  obstructed  smoking  COPD
patients in the study by Linden et al. may explain why
in  our  study  no  differences  in  GR  binding  affinity
were  found  between  smoking  and  nonsmoking
obstructed COPD patients. Furthermore, we did not
find any difference in the binding affinity of the GR in
COPD patients when compared with values found in
controls.  Different  inflammatory  mediators  may  be
involved in COPD and in smoking and it remains to be
established which mediators actually alter GR charac-
teristics. The actual mechanisms by which inflamma-
tory  mediators,  present  in  the  airways  of  smoking
controls can induce a decrease in GR binding affinity
in HBEC remain to be established. Others have shown
that  altered  expression  of  glucocorticoid-regulated
proteins appears to be mediated via interaction of the
modulatory  domain  of  the  GR  with  transcriptional
factors,  such  as  AP-1.
24–26 Overexpression  of  AP-1
interferes  with  the  function  of  the  modulatory
domain  of  the  GR.  Because  cytokines  can  induce
elevated levels of AP-1, it has been suggested that this
may provide a plausible explanation for the decreased
ligand  binding  affinity  of  nuclear  GR  for  gluco-
corticoids found in T cells after incubation with IL-2
and IL-4.
24 –26 Perhaps, a similar explanation could be
given for the decreased GR binding affinity in HBEC
induced by inflammatory mediators in the airways of
smoking controls. Another explanation for decreased
GR binding affinity  could be a modulating effect of
inflammatory  mediators  in  the  airways  of  smoking
controls  on  the  expression  and  phosphorylation  of
heat  shock proteins, which are associated with  the
unliganded GR.
27,28 Bacterial products and cytokines
can regulate the expression and phosphorylation of
heat  shock  proteins  and  this  may  modulate  gluco-
corticoid binding to the GR.
27,28 Further studies are
necessary  to  clarify  the  exact  mechanism  of  the
effects of these inflammatory mediators found in the
airways of smoking controls on GR.
We did not find any difference in the number of GR
between  COPD patients and  controls, nor between
smoking and nonsmoking controls. However, it cannot
be  excluded  that  differences,  present  between  the
groups  in  vivo,  disappeared  during  isolation  and
culture of these cells. We tried to clarify this issue and
tested  cultures  of  HBEC  at  subsequent  passages.
Similar numbers of GR and Kd values were found in
subsequent  passages.  Others  have  found  that
increased  GR  numbers  and  decreased  GR  binding
affinity  in  T  cells  from  steroid  resistant  asthmatic
patients  reverted  to  normal  after  48 h  in  culture.
29
It  would  be  interesting  to  study  GR  number  and
affinity  directly  on  the  bronchial  tissue  or  directly
after  cell  isolation.  However,  performance  of  a
3H-dexamethasone binding assay, the most sensitive
method to determine GR number and affinity, directly
after cell isolation is not possible, because of the low
cell number obtained. We are currently working on a
method to quantify GR number in small cell samples by
flow cytometry using several GR specific antibodies.
To  our  knowledge,  no  other  studies  have  been
published on GR number and Kd values in HBEC from
smoking  and  nonsmoking  COPD  patients  and  con-
trols.  Until  now,  most  investigations  have  concen-
trated  on  the  analysis  of  GR  in  PBMC,  comparing
asthmatics  with  healthy  individuals.
30,31 No  differ-
ences  in  GR  number  or  GR  binding  affinity  were
found  between  PBMC  from  asthmatics  and  con-
trols.
23,29 Recently, Kam et al.
10 showed that PBMC
from  steroid  resistant  asthmatics  had  a  significantly
reduced  GR  binding  affinity  and  an  increased  GR
number when compared with normal subjects. Oth-
ers have claimed that the clinical response to gluco-
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number or affinity.
32They suggested that the ability of
GR  to  bind  to  their  DNA  binding  sites  (GRE)  is
impaired.  Further  studies  are  necessary  to  clarify
whether  the  clinical  response  to  inhaled  gluco-
corticoids  is  related  to  the  number  and  binding
affinity  of  GR  and  which  cells  are  involved  in  this
response.  As  only  a  subgroup  of  COPD  patients
responds to inhaled glucocorticoids, it is of interest to
look in resistant patients for correlations between the
clinical response to glucocorticoids and the number
of GR and their Kd in bronchial epithelial cells.
33
In  conclusion,  we  demonstrated  that  cultured
HBEC possess a single class of specific GR and that the
binding affinity of GR in HBEC from smoking controls
was  significantly  decreased  when  compared  with
values found  in  nonsmoking controls. These  results
provide further  evidence that  the  bronchial  epithe-
lium  may  be  an  actual  target  for  glucocorticoid
therapy.  Furthermore,  our  findings  are  the  first
indication that altered GR characteristics are present
in cultured HBEC from smokers. We hypothesize that
this may  result from the inflammation found in  the
airways from smokers.
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